Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Maternal Hypertension
Interventions: Clinical blood pressure threshold of SBP >= 160 mmHg for acute treatment of hypertension, Clinical blood pressure threshold of SBP >= 180 mmHg for acute treatment of hypertension; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Female only
Enrollment: 1,003 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pre-eclampsia
Interventions: Placebo, RLX030; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Mobile, Alabama • Lexington, Kentucky • Louisville, Kentucky + 1 more

Conditions: Glaucoma, Intraocular Pressure, Optic Neuropathy
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: Not listed
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension, Heart Failure
Interventions: Clevidipine, Standard of Care IV antihypertensive; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 9
States / cities: Montgomery, Alabama • Inglewood, California • Baton Rouge, Louisiana + 6 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Not listed
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 39
States / cities: Culver City, California • La Jolla, California • Los Angeles, California + 35 more

Conditions: Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Chronic Disease, Stroke, Heart Failure Chronic, Hypertension (HTN)
Interventions: Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM); Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Preeclampsia Postpartum
Interventions: Remote Patient Monitoring; Device
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Glaucoma
Interventions: Ahmed implant, Baerveldt implant; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pulmonary Arterial Hypertension
Interventions: Sitaxsentan; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more

Conditions: Primary Open Angle Glaucoma, Hypertension Ocular
Interventions: Pulsed Electromagnetic Field Therapy, Seawater eyedrops; Device · Drug
Lead sponsor: American Society Of Thermalism And Climatology Inc; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Systemic Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more

Conditions: Glaucoma
Interventions: Bimatoprost; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Renal Insufficiency, Chronic
Interventions: 6R-BH4, 6R-BH4 placebo, Folic acid, Exercise training, Stretching, Histidine and beta-alanine supplementation, Histidine and beta-alanine placebo; Drug · Other · Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: Pre-hypertension, Hypertension
Interventions: Potassium, Magnesium, Citrate, Potassium Chloride; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 95 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: CONSULT-BP Educational Intervention; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: Not listed
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Barre, Massachusetts • Uxbridge, Massachusetts • Worcester, Massachusetts

Conditions: Pulmonary Arterial Hypertension
Interventions: Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI); Combination Product
Lead sponsor: Respira Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 26
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more

Conditions: Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer, Coronary Artery Disease, Congestive Heart Failure, Diabetes, Glaucoma, Hemophilia, Hypertension, Hyperthyroidism, Hypothyroidism, Myasthenia Gravis, Osteoporosis, Osteopenia, Renal Failure, Renal Insufficiency, Sickle Cell Disease, Stroke
Interventions: MAPLE; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis, Hypertension
Interventions: naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid, naproxen 500 mg bid, ibuprofen 600 mg tid; Drug
Lead sponsor: NicOx; Industry
Eligibility: 40 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 57
States / cities: Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 54 more

Conditions: Pulmonary Hypertension, Lung Disease, Sickle Cell Disease, Cardiac Transplant, Lung Transplant
Interventions: Inhaled Nitric Oxide; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 5 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 3
States / cities: Denver, Colorado • Providence, Rhode Island

Conditions: Sarcoidosis, Pulmonary Hypertension
Interventions: Observation; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pulmonary Hypertension
Interventions: Iloprost PD-6, Iloprost PD-15; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Phoenix, Arizona • La Jolla, California • Iowa City, Iowa + 8 more

Conditions: Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypertension, End Stage Renal Disease
Interventions: Vasopressin - Very Low Dose, Vasopressin - Low Dose, Placebo Comparator; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Perinatal Outcomes Following Change in Clinical Criteria in for Treatment of Maternal Hypertension

Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia

Comparing Rates of Glaucoma in Professional Wind Versus Non-Wind Instrument Players

Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)

18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

Improving the Collaborative Health of Adult Dyads

Guideline-directed Management and Therapy (GDMT) for the Prevention of Postpartum Cardiac Dysfunction in Preeclamptic African American Women

Ahmed Versus Baerveldt Comparison Study

A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension

Effects of Magnetic Therapy and Seawater Combined in Decreasing Intraocular Presion.

Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)

A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension

Neurovascular Transduction During Exercise in Chronic Kidney Disease

Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients

COmmuNity-engaged SimULation Training for Blood Pressure Control

Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

Study of an Intervention to Improve Problem List Accuracy and Use

To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension

Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide

Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

Natural History of Noncirrhotic Portal Hypertension

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease